NASDAQ:AKBAAkebia Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Akebia Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $10.50 +0.22 (+2.14 %) (As of 08/13/2020 04:00 PM ET) Add Compare Share Today's Range$9.98Now: $10.50▼$10.5350-Day Range$10.28MA: $11.99▼$13.5852-Week Range$2.99Now: $10.50▼$13.71Volume1.46 million shsAverage Volume1.53 million shsMarket Capitalization$1.50 billionP/E RatioN/ADividend YieldN/ABeta1.41 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingAkebia Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.67, Akebia Therapeutics has a potential upside of 49.2% from its current price of $10.50.Amount of Analyst CoverageAkebia Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesAkebia Therapeutics has received 382 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAkebia Therapeutics has received 318 “underperform” votes. (Add your “underperform” vote.)Community SentimentAkebia Therapeutics has received 54.57% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Akebia Therapeutics and other stocks. Vote “Outperform” if you believe AKBA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AKBA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAkebia Therapeutics does not currently pay a dividend.Dividend GrowthAkebia Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akebia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $128,486.00 in company stock.Percentage Held by InsidersOnly 2.55% of the stock of Akebia Therapeutics is held by insiders.Percentage Held by Institutions70.08% of the stock of Akebia Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Akebia Therapeutics are expected to grow in the coming year, from ($1.59) to ($0.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akebia Therapeutics is -3.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akebia Therapeutics is -3.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkebia Therapeutics has a P/B Ratio of 3.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.53 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AKBA Previous Symbol CUSIPN/A CIK1517022 Webwww.akebia.com Phone617-871-2098Debt Debt-to-Equity Ratio0.26 Current Ratio1.59 Quick Ratio1.07Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$335 million Price / Sales4.49 Cash FlowN/A Price / Cash FlowN/A Book Value$3.32 per share Price / Book3.16Profitability EPS (Most Recent Fiscal Year)($1.63) Net Income$-279,660,000.00 Net Margins-113.35% Return on Equity-54.01% Return on Assets-28.88%Miscellaneous Employees324 Outstanding Shares143,317,000Market Cap$1.50 billion Next Earnings Date11/10/2020 (Estimated) OptionableOptionable $10.50 +0.22 (+2.14 %) (As of 08/13/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive AKBA News and Ratings via Email Sign-up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Akebia Therapeutics (NASDAQ:AKBA) Frequently Asked Questions How has Akebia Therapeutics' stock been impacted by Coronavirus? Akebia Therapeutics' stock was trading at $6.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AKBA shares have increased by 51.3% and is now trading at $10.50. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Akebia Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Akebia Therapeutics. When is Akebia Therapeutics' next earnings date? Akebia Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Akebia Therapeutics. How were Akebia Therapeutics' earnings last quarter? Akebia Therapeutics Inc (NASDAQ:AKBA) posted its quarterly earnings data on Monday, August, 10th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.46) by $0.02. Akebia Therapeutics had a negative net margin of 113.35% and a negative return on equity of 54.01%. View Akebia Therapeutics' earnings history. What price target have analysts set for AKBA? 6 equities research analysts have issued 12-month target prices for Akebia Therapeutics' shares. Their forecasts range from $12.00 to $18.00. On average, they anticipate Akebia Therapeutics' share price to reach $15.67 in the next year. This suggests a possible upside of 49.2% from the stock's current price. View analysts' price targets for Akebia Therapeutics. Has Akebia Therapeutics been receiving favorable news coverage? News coverage about AKBA stock has been trending negative recently, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Akebia Therapeutics earned a news sentiment score of -2.4 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Akebia Therapeutics. Are investors shorting Akebia Therapeutics? Akebia Therapeutics saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 9,640,000 shares, an increase of 61.5% from the June 15th total of 5,970,000 shares. Based on an average trading volume of 1,760,000 shares, the days-to-cover ratio is presently 5.5 days. View Akebia Therapeutics' Short Interest. Who are some of Akebia Therapeutics' key competitors? Some companies that are related to Akebia Therapeutics include Myokardia (MYOK), Ultragenyx Pharmaceutical (RARE), United Therapeutics (UTHR), Zai Lab (ZLAB), HUTCHISON CHINA/S (HCM), Schrodinger (SDGR), Allakos (ALLK), Blueprint Medicines (BPMC), Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), FibroGen (FGEN), Legend Biotech (LEGN), HYPERA S A/S (HYPMY), Amicus Therapeutics (FOLD) and Nektar Therapeutics (NKTR). View all competitors. What other stocks do shareholders of Akebia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer LP Unit (ET), Corbus Pharmaceuticals (CRBP), AT&T (T), TherapeuticsMD (TXMD) and FireEye (FEYE). Who are Akebia Therapeutics' key executives? Akebia Therapeutics' management team includes the following people: Mr. John P. Butler MBA, CEO, Pres & Director (Age 55)Mr. Jason A. Amello, Sr. VP, CFO & Treasurer (Age 51)Dr. Rita Jain, Sr. VP & Chief Medical Officer (Age 57)Ms. Nicole R. Hadas, SVP, Chief Legal Officer & Sec. (Age 46)Mr. Douglas Jermasek, VP of Marketing & Strategy What is Akebia Therapeutics' stock symbol? Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA." Who are Akebia Therapeutics' major shareholders? Akebia Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (1.36%), Candriam Luxembourg S.C.A. (0.94%), Sofinnova Investments Inc. (0.48%), Bank of New York Mellon Corp (0.48%), Marshall Wace North America L.P. (0.33%) and Marshall Wace LLP (0.28%). Company insiders that own Akebia Therapeutics stock include Dell Faulkingham, Jason Amello, John P Butler, Maxine Gowen, Michel Dahan, Nicole R Hadas, Steven C Gilman and Steven Keith Burke. View institutional ownership trends for Akebia Therapeutics. Which institutional investors are selling Akebia Therapeutics stock? AKBA stock was sold by a variety of institutional investors in the last quarter, including Leap Investments LP, UBS Group AG, Virtus ETF Advisers LLC, Lincoln Capital Corp, Fifth Third Bancorp, Dupont Capital Management Corp, Foundry Partners LLC, and Stanley Laman Group Ltd.. Company insiders that have sold Akebia Therapeutics company stock in the last year include Dell Faulkingham, Jason Amello, Maxine Gowen, Michel Dahan, and Nicole R Hadas. View insider buying and selling activity for Akebia Therapeutics. Which institutional investors are buying Akebia Therapeutics stock? AKBA stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., FMR LLC, Sofinnova Investments Inc., Marshall Wace North America L.P., Marshall Wace LLP, Federated Hermes Inc., Bank of Montreal Can, and EAM Investors LLC. Company insiders that have bought Akebia Therapeutics stock in the last two years include John P Butler, Steven C Gilman, and Steven Keith Burke. View insider buying and selling activity for Akebia Therapeutics. How do I buy shares of Akebia Therapeutics? Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Akebia Therapeutics' stock price today? One share of AKBA stock can currently be purchased for approximately $10.50. How big of a company is Akebia Therapeutics? Akebia Therapeutics has a market capitalization of $1.50 billion and generates $335 million in revenue each year. The biopharmaceutical company earns $-279,660,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. Akebia Therapeutics employs 324 workers across the globe. What is Akebia Therapeutics' official website? The official website for Akebia Therapeutics is www.akebia.com. How can I contact Akebia Therapeutics? Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected] This page was last updated on 8/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
